Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study identified a specific SNP in the CACNB4 gene associated with a higher risk of chemotherapy-induced alopecia in breast cancer patients, which may help develop interventions to improve their quality of life.

In this study, Mononuclear Cells provided site-specific protection against chemotherapy-induced alopecia in rats treated with Ara-C, but not with CTX or VP-16, while PRP showed no protective effect.

This study details a case of a 20-year-old woman with APECED syndrome and alopecia areata who experienced complete scalp hair regrowth and improved quality of life after nine months of ruxolitinib treatment, highlighting the drug's effectiveness for severe AA linked to AIRE gene mutation.

This article summarizes dermatologic adverse events in patients treated with afatinib in clinical trials and discusses strategies for managing these side effects, without providing new clinical results.

This review discusses the repurposing of auranofin for oncological and non-oncological uses and highlights its early-stage clinical trial findings, suggesting further exploration of its therapeutic potential.

In this study, dose-response modeling predicted that once-daily abrocitinib doses of 100 mg and 200 mg may provide a clinically meaningful response in treating moderate-to-severe atopic dermatitis compared to placebo.

In this study, tebentafusp-tebn improved overall survival in patients with metastatic uveal melanoma compared to standard therapies, despite higher rates of significant adverse events.

This study found that baicalin delivery through polymeric nanocapsules significantly enhanced its anticancer activity in breast cancer cell lines MCF-7 and MDA-MB-231.

This source reports that trastuzumab deruxtecan improves outcomes in HER2-positive and HER2-low metastatic breast cancer, emphasizing the need for careful adverse event monitoring, particularly for interstitial lung disease, and managing emetic risk to maximize benefits.

This study found that S-1 combined with paclitaxel was an effective and tolerable second-line chemotherapy option for advanced gastric cancer, with some patients experiencing partial responses and manageable adverse reactions.

This study found that the novel anti-HER2 antibody RC48 demonstrated promising activity and manageable safety in patients with HER2-overexpressing, advanced gastric or gastroesophageal junction cancer after at least two prior chemotherapy lines.

In this study, induction nab-paclitaxel plus cisplatin, combined with nimotuzumab and IMRT, followed by S-1 adjuvant chemotherapy, showed excellent survival benefits with tolerable toxicities for stage N3 nasopharyngeal carcinoma patients.

This study used machine learning to identify FDA-approved drugs afatinib, neratinib, and zanubrutinib as potential KRASG12C inhibitors for resistant non-small-cell lung cancer, highlighting the potential of AI in drug repurposing.

In this study, a nanoparticle system codelivering diphenylcyclopropenone and rapamycin successfully induced immune tolerance and promoted hair regrowth in a mouse model of alopecia areata, offering a promising new therapeutic strategy for this autoimmune condition.

This review highlights the dual nature of Abrus precatorius as both a traditional medicine and a toxin, emphasizing its rich phytochemical profile and potential therapeutic applications, while noting the need for rigorous quality control and clinical trials to ensure safety and efficacy.

In this in vitro study, researchers found that a combination of soursop leaf extract and doxorubicin moderately enhanced the anti-cancer effect against MCF-7 breast cancer cells, but they did not report on reducing doxorubicin's side effects.

This study found that neoadjuvant chemotherapy followed by interval debulking surgery led to better quality of life and lower perioperative morbidity compared to primary debulking surgery in advanced epithelial ovarian cancer patients with high tumor load.

In this phase I study, CT-707, a new ALK inhibitor, showed a 77% response rate among Chinese patients with advanced ALK-rearranged non-small cell lung cancer, suggesting clinical effectiveness despite some adverse events like diarrhea and liver enzyme elevation.

In this study, Ocoxin used alongside chemotherapy may improve patients' tolerance to treatment and their quality of life without significant safety concerns, although further research is needed.

This study found that combining the PAXMAN scalp cooling system with HairRepro MEDI α lotion led to a 50% success rate in reducing chemotherapy-induced alopecia and achieved complete hair regrowth by 3 months in Japanese breast cancer patients, suggesting enhanced efficacy over scalp cooling alone.

This study found that sodium valproate nanospanlastics could be an effective and safer method for treating androgenic alopecia, with results comparable to minoxidil but fewer side effects.

This study found that irreversible and severe alopecia can occur following docetaxel or paclitaxel chemotherapy in breast cancer patients.

In this study, broccoli sprout extract and sulforaphane were found to reduce cell viability, suppress growth, and induce apoptosis in breast cancer cells, and oral broccoli sprout extract inhibited tumor growth in animal models, suggesting it may be effective in managing breast cancer.

In this phase II clinical study, combining anlotinib with standard platinum-based chemotherapy showed promising outcomes and prognosis in treating extensive small-cell lung cancer, with high disease control and response rates.

This review discusses the potential of cold atmospheric plasma as a selective antitumor therapy for breast cancer but reports no clinical results, emphasizing its promise and the challenges to its use in precision oncology.

This study found that eliminating senescent cells using senolytic drugs effectively prevented and reversed paclitaxel-induced peripheral neuropathy in mice.

In this study, four children with recurrent atypical teratoid rhabdoid tumors experienced disease stabilization or regression after treatment with alisertib, suggesting its potential role in future trials for this condition.

Paclitaxel chemotherapy causes premature aging and damage to hair follicles, potentially leading to permanent hair loss.

This review examines the development and challenges of using PROTACs, a targeted protein degradation strategy, to treat cancer by degrading specific proteins like PARPs and GPX4, highlighting issues such as target diversification and bioavailability.

In this descriptive study, researchers assessed the most common short-term side effects of anthracycline and taxane-based chemotherapy in 122 Moroccan women with localized breast cancer, documenting frequent systemic, gastrointestinal, dermatological, neurological, musculoskeletal, and ocular toxicities.